Replimune Group stock hits 52-week high at 16.2 USD
Replimune Group Inc's stock soared to a 52-week high of $16.20, a testament to the company's impressive growth. The stock currently trades 1% below its peak, marking a significant 165.99% increase over the past year. Recent momentum has been especially strong, with a 119% gain in the past six months and a 61% return year-to-date.
Analysts remain bullish, with price targets ranging from $14 to $24. However, InvestingPro analysis indicates the stock is currently overvalued. The FDA's accelerated approval of Replimune Group's cancer treatment, TUDRIQEV, combined with nivolumab, has propelled the company to new heights. This approval marks the first of an oncolytic virus combined with a checkpoint inhibitor for advanced melanoma.
Following this breakthrough, Wedbush and Leerink both upgraded Replimune's stock rating to Outperform, raising price targets to $19 and $17 respectively. Cantor Fitzgerald echoed this optimism, reiterating an Overweight rating and highlighting Tudriqev's potential for advanced melanoma. As anticipation builds for Replimune's upcoming earnings report, the company's future in the biotech sector appears promising.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
